About Hemostemix
Hemostemix Inc. is a clinical-stage regenerative medicine company advancing investigational autologous cell therapy programs for vascular and ischemic disease.
Clinical-Stage Biotechnology Company
Our Founder’s Story
Roger Bergersen was the principal founder of TheraVitae Inc., which later became Hemostemix Inc.
Roger was a key figure in developing and championing our autologous stem cell therapy, originally known as VesCell™ and now referred to as ACP-01 (Angiogenic Cell Precursors).
Bergersen’s involvement stemmed from his personal experience. In 2005, facing critical heart disease, he traveled to Bangkok, Thailand for experimental treatment. That treatment involved an early version of our autologous stem cell product ACP-01 derived from his own blood. The treatment involved harvesting his blood, processing it to isolate angiogenic precursor cells, multiplying them, then injecting them into the affected area to promote new blood vessel formation (angiogenesis) and tissue repair.
He claimed that this compassionate-use or early treatment saved his life and so dramatically improved his condition that he founded the company to make the technology more widely available.
Since that time, Hemostemix has conducted multiple clinical studies on ACP-01 for conditions including critical limb ischemia (CLI), ischemic cardiomyopathy, angina, vascular dementia, and other ischemic diseases. Our research continues as we move toward new clinical trials.
ACP-01 has been administered to hundreds of patients across trials and compassionate programs, with published results showing safety, ulcer healing, pain resolution, and sustained benefits in some cases up to 4.5+ years, and longer in individual compassionate cases such as one patient highlighted at 13 years and another at 17+ years post-treatment. Roger Bergersen’s case does not appear to have been an anomaly.
Bergersen received his initial treatment in 2005. He passed away in his sleep on February 27, 2020, having lived another 15 years following his procedure. He remained deeply passionate about ACP-01 and dedicated his efforts to advancing the technology for others facing serious ischemic disease.
Hemostemix announced his passing in March 2020, highlighting his foundational role and his commitment to expanding research in autologous angiogenic therapies.
Clinical Development and Research
Hemostemix has conducted multiple Phase I and Phase II clinical investigations evaluating ACP-01 across ischemic and cardiovascular indications.
Clinical programs have included:
Chronic Limb Threatening IschemiaPeripheral Arterial Disease
Ischemic Cardiomyopathy
Heart Failure
Angina
Vascular Dementia
Non-healing Wounds
Chronic Pain
Longevity
Published peer-reviewed findings have evaluated safety and functional outcomes within defined patient populations.
ACP-01 remains investigational in all indications and continues to be evaluated through structured clinical programs.
Leadership and Governance
Hemostemix is led by a management team and board with experience in biotechnology, clinical research, corporate development, and operational strategy.
Commitment to Responsible Development
Hemostemix is committed to:
Ethical clinical research
Transparent communication with investors and stakeholders
Compliance with applicable regulatory frameworks
Continued advancement of investigational therapies through structured scientific evaluation
Disclaimer